Table 2 Univariate association between clinical and pathology features and BC recurrence and survival

Age^a

1.04 [1.02–1.06]

 < 0.000005*

1.05 [1.03–1.07]

 < 0.0000001*

1.04 [1.02–1.06]

0.00013*

Age > 50 (vs. < 50)

2.01 [1.04–4.11]

0.037*

2.90 [1.37–6.17]

0.0056*

1.88 [0.87–4.08]

0.11

ERβ1 > 40% (vs. ERβ1 < 40%)

1.61 [0.93–2.76]

0.086

1.20 [0.70–2.05]

0.508

1.22 [0.65–2.27]

0.538

ERβ1 Allred 1–4 (vs. ERβ1 Allred 0)

0.90 [0.39–2.08]

0.83

1.81 [0.81–4.04]

0.145

1.31 [0.53–3.26]

0.560

ERβ1 Allred > 5 (vs. ERβ1 Allred 0)

1.70 [0.85–3.39]

0.13

1.76 [0.82–3.77]

0.149

1.47 [0.64–3.36]

0.359

Size^b

1.02 [1.00–1.04]

0.016*

1.03 [1.01–1.05]

0.0003*

1.02 [0.99–1.04]

0.063

LN status positive (vs. LN status negative)

2.97 [1.65–5.37]

0.0003*

3.30 [1.79–6.08]

0.0001*

2.91 [1.47–5.73]

0.002*

Grade 3 (vs. Grades 1 and 2)

1.32 [0.41–4.22]

0.643

2.18 [0.53–9.01]

0.283

1.45 [0.35–6.03]

0.605

Stage IIA

3.16 [1.28–7.79]

0.012*

2.51 [1.05–5.98]

0.039*

4.99 [1.46–17.07]

0.010*

Stage IIB

2.45 [0.85–7.09]

0.098

2.67 [0.98–7.23]

0.054

3.74 [0.93–14.97]

0.062

Stage III/IV

8.00 [3.10–20.62]

0.000017*

6.92 [2.76–17.34]

0.000037*

9.60 [2.67–34.60]

0.00054*

Surg WLE (vs. mastectomy)

0.76 [0.43–1.33]

0.33

0.60 [0.34–1.06]

0.079

0.56 [0.28–1.12]

0.101

RT Yes (vs. no)

0.89 [0.48–1.62]

0.679

0.86 [0.46–1.60]

0.635

0.85 [0.41–1.74]

0.648

Chemotherapy Yes (vs. no)

0.38 [0.21–0.68]

0.0011*

0.33 [0.18–0.61]

0.0004

0.42 [0.20–0.86]

0.018*